Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when VERA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsVera Therapeutics names Nancy Bowman Chief Regulatory Officer, effective August 3
Filed July 9, 2026 · Period ending July 9, 2026 · ~1 min read
Key Changes
-
medium
Nancy Bowman, M.D., Ph.D. appointed Chief Regulatory Officer effective August 3, 2026, succeeding William Turner who transitions to Special Advisor for Regulatory Affairs.
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR →
Summary
Vera Therapeutics is executing a planned leadership transition in its regulatory function. William Turner will step down as Chief Regulatory Officer on August 3, 2026, but remain with the company as Special Advisor for Regulatory Affairs. Nancy Bowman, M.D., Ph.D., will assume the CRO role on the same date.
For retail investors, this represents a routine executive succession with continuity features that reduce transition risk. Turner's retention as Special Advisor suggests the company values his institutional knowledge and wants to ensure a smooth handover. Bowman's dual M.D./Ph.D. credentials indicate strong scientific and medical expertise, which is relevant for a biotech company navigating regulatory pathways. The advance notice and overlapping advisory role point to an orderly, planned transition rather than an unexpected departure.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
William Turner will no longer serve as the Company’s Chief Regulatory Officer and will transition to the role of Special Advisor for Regulatory Affairs, effective as of August 3, 2026. Nancy Bowman, M.D., Ph.D., will succeed Mr. Turner as the Company’s Chief Regulatory Officer, effective as of August 3, 2026.
The company is replacing its Chief Regulatory Officer. William Turner is stepping down from the CRO role but remaining with the company as Special Advisor for Regulatory Affairs. Nancy Bowman, who holds both M.D. and Ph.D. degrees, will take over as CRO. Both changes take effect August 3, 2026. This appears to be a planned transition rather than an abrupt departure, as Turner is staying on in an advisory capacity.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 9, 2026 · How we verify